Ranbaxy Laboratories has settled all matters relating to possible patent litigation with GlaxoSmithKline relating to Sumatriptan Succinate Tablets, the generic version of GlaxoSmithKline's Imitrex Tablets.

As part of the settlement, Ranbaxy may get to distribute the generic version of Sumatriptan Succinate Tablets (in the 25 mg, 50 mg and 100 mg strengths) in the United States with an expected launch date in December 2008. The annual market sales for Sumatriptan Succinate (Imitrex) were $985 million.